Other News

American Medical Association (AMA) Grants Prevencio Three CPT® PLA Reimbursement Codes for Novel AI-driven Cardiac HART® Blood Tests

Receipt of dedicated CPT® codes mark important commercialization milestone to pursue reimbursement for Prevencio’s multi-protein HART CADhs®, HART CVE®, and HART KD® Blood Tests KIRKLAND, Wash.–(BUSINESS WIRE)–Prevencio, Inc., The AI-driven Cardiac Company™, today announces that the American Medical Association (AMA) has assigned three new, dedicated Current Procedural Terminology (CPT®) Proprietary Laboratory Analysis […]

Dr. Stephen J. Hoenig Completes First-of-its-Kind Procedure at The Vascular Care Group, Leominster

Minimally invasive procedure decreases recovery time and demonstrates new opportunities in outpatient care LEOMINSTER, Mass.–(BUSINESS WIRE)–The Vascular Care Group (TVCG), a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, today announced Stephen J. Hoenig M.D. successfully completed a percutaneous femoral-popliteal artery bypass at the Leominster, Mass. […]

Medtronic Announces Approval of the Evolut™ PRO TAVR System in China

First Medtronic TAVR system approved in China for patients with symptomatic severe aortic stenosis DUBLIN, Jan. 10, 2022 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the National Medical Products Administration (NMPA) has approved the CoreValve™ Evolut™ PRO TAVR system for the treatment of severe aortic stenosis (AS) […]

DiNAQOR Announces Research Collaboration with Children’s Medical Research Institute to Develop Novel, Cardiac Specific Capsids

DiNAQOR retains option rights to own the co-developed capsids for the fields of cardiovascular and kidney disease ZURICH-SCHLIEREN, Switzerland and WESTMEAD, NSW, Australia, Jan. 10, 2022 /PRNewswire/ — DiNAQOR, a genetic medicine platform company focused on addressing severe inherited cardiac diseases, today announced it has entered into a research collaboration with Children’s Medical Research Institute (CMRI) in Australia to develop […]

Breakthrough in Device Therapy for Patients with Late-Stage Heart Disease

Calon Cardio-Technology Ltd. and Leviticus-Cardio Ltd. announce the joint Development and Testing of a Wireless, Fully Implantable, Long-Term Blood Pump. SWANSEA, Wales and TEL AVIV, Israel, Jan. 10, 2022 /PRNewswire/ — Severe heart failure is the most life-threatening medical condition in all age groups across the globe. Implantable heart pumps, known as Ventricular Assist […]

Amarin Provides Preliminary 2021 Revenue and Outlook for 2022

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today provided a business update, including preliminary unaudited full-year 2021 revenue results. Amarin plans to discuss these results and expectations with investors in connection with the 40th Annual J.P. Morgan Healthcare Conference at which Amarin is […]

LianBio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

EXPLORER-CN trial designed to support regulatory filing in Mainland China SHANGHAI, China and PRINCETON, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in […]

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results

MINNEAPOLIS, Jan. 10, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited fourth quarter and full year 2021 revenue results, and provided a 2022 business outlook. Fourth Quarter […]

Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs

VERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022 ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022 Preclinical Data in Non-Human Primates Demonstrate Potential to Re-Dose or Sequentially Dose Base Editing Programs CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, […]